Last updated 11 days ago
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
4935 patients around the world
Available in Puerto Rico, Spain, Argentina, United States
Boehringer Ingelheim
2Research sites
4935Patients around the world
This study is for people with
Obesity
Cardiovascular disease
Established cardiovascular disease
Renal disease
Chronic kidney disease
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years.Body mass index (BMI) ≥27 kg/m2 at screening with established cardiovascular disease (CVD) and/or at least 2 weight-related complications or risk factors for CVD OR BMI ≥30 kg/m2 at screening with established CVD or chronic kidney disease (CKD), and/or at least 2 weight-related complications or risk factors for CVD.
- Previous treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists within 3 months before screening.Type 1 diabetes.Less than 3 months between the last dose of GLP-1R agonists and GLP-1R agonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations and screening.Known clinically significant gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).
Sites
CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegiani
Recruiting
Centro Especialidades Médicas SRL (CEMEDIC)
Recruiting
SponsorBoehringer Ingelheim
Conditions
ObesityEstablished cardiovascular diseaseChronic kidney disease
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06077864
